{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:52:38Z","timestamp":1758970358015},"reference-count":31,"publisher":"Wiley","issue":"s75","license":[{"start":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T00:00:00Z","timestamp":1040256000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:p>Desloratadine, a potent, once\u2010daily, orally active, nonsedating, histamine H<jats:sub>1<\/jats:sub>\u2010receptor antagonist, inhibits the release of histamine and other inflammatory mediators. Once\u2010daily desloratadine therapy rapidly reduces the symptoms of perennial allergic rhinitis and seasonal allergic rhinitis (SAR), reduces the use of inhaled albuterol by patients with SAR and concomitant asthma, and improves symptoms and quality of life in patients with chronic idiopathic urticaria. An open\u2010label, observational study in SAR patients revealed that desloratadine therapy significantly reduced nasal, ocular, dermal, asthma, and total symptoms, and enabled half of the patients with concomitant asthma to reduce their use of asthma medications. Globally, more than 91% of patients and physicians judged desloratadine to have excellent or good efficacy, and more than 98% judged it to have excellent or good tolerability. Furthermore, desloratadine therapy improved quality of life, decreasing by more than 10\u2010fold the percentage of patients whose daily activities and\/or sleep were moderately or severely affected by SAR. Allergic rhinitis, a major chronic airway disease that is a risk factor for asthma, warrants extended diagnostic procedures and well\u2010tolerated therapy that encompasses the entire airway, addresses multiple steps in the allergic inflammatory cascade, and is effective on nasal, ocular, dermal, asthma, and total symptoms.<\/jats:p>","DOI":"10.1034\/j.1398-9995.57.s75.3.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T01:51:23Z","timestamp":1047347483000},"page":"13-18","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic points of intervention and clinical implications: role of desloratadine"],"prefix":"10.1111","volume":"57","author":[{"given":"C.","family":"Bachert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,12,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2500\/105065800781329582"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00526.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237378"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.1997.tb00156.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(00)91551-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.114239"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb00745.x"},{"issue":"68","key":"e_1_2_6_10_2","first-page":"112","article-title":"Binding and antiallergic characteristics of desloratadine. Abstract 325","volume":"56","author":"Lippert U","year":"2001","journal-title":"Allergy"},{"key":"e_1_2_6_11_2","first-page":"S44.","article-title":"Loratadine (L) reduces RANTES release by an epithelial cell line","volume":"99","author":"Lebel B","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.1995.tb00257.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01130.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb01133.x"},{"issue":"73","key":"e_1_2_6_15_2","first-page":"145","article-title":"Effects of desloratadine (DL) on human monocyte activity in\u2010vitro","volume":"57","author":"Bachert C","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb01154.x"},{"issue":"73","key":"e_1_2_6_17_2","first-page":"155","article-title":"Wasp venom\u2010induced IL\u20105, IL\u201010, and IFN\u2010\u03b3 secretion from human PBMC from patients with wasp venom allergy is diversely inhibited by loratadine, desloratadine and cimetidine","volume":"57","author":"Straff B","year":"2002","journal-title":"Allergy"},{"issue":"73","key":"e_1_2_6_18_2","first-page":"147","article-title":"Immunoregulatory influence of descarboxyloratadine (DCL) on human lymphocytes","volume":"57","author":"Wittmann M","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.00102.x"},{"issue":"73","key":"e_1_2_6_20_2","first-page":"146","article-title":"Effects of desloratadine (DL) on Th2\u2010cytokine secretion of peripheral blood leukocytes from patients with allergic rhinitis, patients with allergic asthma, and healthy controls","volume":"57","author":"Biller H","year":"2002","journal-title":"Allergy"},{"issue":"63","key":"e_1_2_6_21_2","first-page":"276","article-title":"Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation","volume":"55","author":"Agrawal DK","year":"2000","journal-title":"Allergy"},{"issue":"73","key":"e_1_2_6_22_2","first-page":"38","article-title":"Influence of desloratadine on the chemotactic activity of human polymorphonuclear leukocytes","volume":"57","author":"Huger M","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(02)81754-7"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(02)81465-8"},{"key":"e_1_2_6_25_2","first-page":"S159","article-title":"Once\u2010daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks","volume":"107","author":"Dubuske L","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200121010-00004"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.00186.x"},{"key":"e_1_2_6_28_2","first-page":"109","article-title":"Desloratadine improved asthma symptoms and reduce bronchodilator use in 2 studies of patients with asthma and SAR","volume":"86","author":"Ratner PH","year":"2000","journal-title":"Allergy Asthma Immunol"},{"issue":"73","key":"e_1_2_6_29_2","first-page":"236","article-title":"The differential impacts of diphenhydramine and desloratadine on vigilance and cognitive functioning in subjects with ragweed induced allergic rhinitis","volume":"57","author":"Wilken JA","year":"2002","journal-title":"Allergy"},{"issue":"73","key":"e_1_2_6_30_2","first-page":"47","article-title":"Treatment of seasonal allergic rhinitis with desloratadine: results of a large German observational study","volume":"57","author":"Plenker A","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_6_31_2","unstructured":"Data on file.Schering\u2010Plough 2002."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222002-00005"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1398-9995.57.s75.3.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1398-9995.57.s75.3.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:15:13Z","timestamp":1695726913000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1398-9995.57.s75.3.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":31,"journal-issue":{"issue":"s75","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1034\/j.1398-9995.57.s75.3.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1398-9995.57.s75.3.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}